Preview

Медицинский Совет

Расширенный поиск

Неклассические эффекты силденафила в клинической медицине: междисциплинарный подход

https://doi.org/10.21518/2079-701X-2018-21-192-202

Полный текст:

Аннотация

В обзорной статье на основе результатов современных клинико-экспериментальных исследований рассматриваются вопросы фармакотерапевтической целесообразности, патогенетической обоснованности и безопасности применения в широкой клинической практике первого и наиболее изученного ингибитора фосфодиэстеразы 5-го типа – силденафила – по «неклассическим» (неэректогенным) показаниям в рамках междисциплинарного подхода в современной медицине. Как известно, в настоящее время ингибиторы фосфодиэстеразы 5-го типа являются как терапией «первой линии» лечения эректильной дисфункции (в виде монотерапии), так и эффективным вариантом монотерапии или комбинированной фармакотерапии симптомов нижних мочевых путей на фоне доброкачественной гиперплазии предстательной железы у мужчин с эректильной дисфункцией. Однако с учетом универсальности и фундаментальности механизмов их фармакологического действия (прежде всего влияние на метаболизм одного из ключевых вазомодуляторов сосудистого русла – оксида азота NO) список потенциальных и перспективных показаний к назначению данных препаратов постоянно расширяется за счет наличия у них различных «неклассических (неэректогенных)» эффектов, что делает их весьма привлекательными для более широкого применения не только в урологической практике, но и в других медицинских специальностях. В статье более подробно и целенаправленно освещены накопленные к настоящему времени научно-практические данные об эффективности применения и потенциальных механизмах действия силденафила в кардиологии, эндокринологии, неврологии, нефрологии, акушерстве и гинекологии, андрологической репродуктологии и онкологии, а также представлены результаты исследований, подтверждающих его безопасность при лечении соответствующих профильных заболеваний.

Об авторах

И. А. Тюзиков
Общество с ограниченной ответственностью «Медицинский центр «Тандем-Плюс»; Общество с ограниченной ответственностью «Медицинский центр «Арго-Премиум»
Россия

Тюзиков Игорь Адамович – кандидат медицинских наук, профессор Российской академии естествознания (РАЕ), заслуженный работник науки и образования, врач уролог-андролог ООО «Медицинский центр «Тандем-Плюс», ООО «Медицинский центр «Арго-Премиум»

150000, г. Ярославль, Первомайский пер., д. 3В, 

156022, г. Кострома, ул. Дачная, д. 48



А. В. Смирнов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Ярославский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия

Смирнов Алексей Владимирович – студент лечебного факультета

150000, г. Ярославль, ул. Революционная, д. 5



Л. В. Смирнова
Общество с ограниченной ответственностью «Медицинский центр «Арго-Премиум»
Россия

Смирнова Лариса Владимировна – врач функциональной диагностики, гинеколог, главный врач

156022, г. Кострома, ул. Дачная, д. 48



И. В. Лесникова
Общество с ограниченной ответственностью «Медицинский центр «Арго-Премиум»
Россия

Лесникова Ирина Вячеславовна – врач акушер-гинеколог

156022, г. Кострома, ул. Дачная, д. 48



Список литературы

1. Hatzimouratidis K., Giuliano F., Moncada I., Muneer A., Salonia A., Verze P., et al. Management of Male Sexual Dysfunction. EAU Guideline, 2017.

2. Gravas S., Cornu J.N., Drake M.J., Gacci M., Gratzke C., Herrmann T.R.W., et al. Management of Non-neurogenic Male LUTS. EAU Guideline, 2017.

3. Derry F., Hultling C., Seftel A.D., Sipski M.L. Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urol. 2002; 60(2 Suppl 2): 49–57.

4. Vrentzos G.E., Paraskevas K.I., Mikhailidis D.P. Erectile dysfunction: a marker of early coronary heart disease. Hellenic J Cardiol. 2007; 48(4): 1851–191.

5. Guay A.T. ED2: erectile dysfunction – endothelial dysfunction. Endocrinol Metab Clin North Am. 2007; 36(2): 453–463. DOI: 10.1016/j.ecl.2007.03.007.

6. Ito M., Nishikawa M., Fujioka M., Miyahara M., Isaka N., Shiku H., et al. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal. 1996; 8: 575–581. DOI: 10.1016/S0898-6568(96)00112-X.

7. Wallis R.M., Corbin J.D., Francis S.H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999; 83: 3C–12C.

8. Loughney K., Hill T.R., Florio V.A., Uher L., Rosman G.J., Wolda S.L., et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3’,5’-cyclic nucleotide phosphodiesterase. Gene. 1998; 216:139–147.

9. Das A., Xi L., Kukreja R.C. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem. 2008; 283: 29572–29585. DOI: 10.1074/jbc.M801547200. Epub 2008 Aug 21.

10. Senzaki H., Smith C.J., Juang G.J., Isoda T., Mayer S.P., Ohler A., et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates betaadrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001; 15: 1718–1726. DOI: 10.1096/fj.00-0538com.

11. Nagendran J., Archer S.L., Soliman D., Gurtu V., Moudgil R., Haromy A., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007; 116: 238–248. DOI: 10.1161/CIRCULATIONAHA.106.655266.

12. Pokreisz P., Vandenwijngaert S., Bito V., Van den Bergh A., Lenaerts I., Busch C., et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119:408–416. DOI: 10.1161/CIRCULATIONAHA.108.822072. Epub 2009 Jan 12.

13. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11:214–222. DOI: 10.1038/nm1175.

14. Vandeput F., Krall J., Ockaili R., Salloum F.N., Florio V., Corbin J.D., et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009; 330: 884–891. DOI: 10.1124/jpet.109.154468.

15. Lukowski R., Krieg T., Rybalkin S.D., Beavo J., Hofmann F. Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. Trends Pharmacol Sci. 2014; 35: 404–413. DOI: 10.1016/j.tips.2014.05.003. Epub 2014 Jun 16.

16. Lukowski R., Rybalkin S.D., Loga F., Leiss V., Beavo J.A., Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci USA. 2010; 107: 5646–5651. DOI: 10.1073/pnas.1001360107. Epub 2010 Mar 8.

17. Ockaili R., Salloum F., Hawkins J., Kukreja R.C. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol. 2002; 283: H1263–H1269.DOI:10.1152/ajpheart.00324.2002.

18. Salloum F.N., Takenoshita Y., Ockaili R.A., Daoud V.P., Chou E., Yoshida K., Kukreja RC. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol. 2007; 42: 453–458. DOI: 10.1016/j.yjmcc.2006.10.015.

19. Bremer Y.A., Salloum F., Ockaili R., Chou E., Moskowitz W.B., Kukreja R.C. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res. 2005; 57: 22–27. DOI: 10.1186/s13054-014-0641-7.

20. Wang X., Fisher P.W., Xi L., Kukreja R.C. Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafilinduced late cardioprotection. J Mol Cell Cardiol. 2008; 44: 105–113. DOI: 10.1016/j.yjmcc.2007.10.006.

21. Salloum F.N., Abbate A., Das A., Houser J.E., Mudrick C.A., Qureshi I.Z., et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008; 294: H1398– H1406. DOI: 10.1152/ajpheart.91438.2007.

22. Salloum F.N., Das A., Thomas C.S., Yin C., Kukreja R.C. Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol. 2007; 43: 545–551. DOI: 10.1016/j.yjmcc.2007.08.014.

23. Chau V.Q., Salloum F.N., Hoke N.N., Abbate A., Kukreja R.C. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011; 300: H2272–H2279. DOI: 10.1152/ajpheart.00654.2010. Epub 2011 Mar 11.

24. Noma K., Oyama N., Liao J.K. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006; 290:C661–C668. DOI: 10.1152/ajpcell.00459.2005.

25. Zusman R.M. Cardiovascular data on sildenafil citrate. Am J Cardiol. 1999; 5(83): 1-2.

26. Guazzi M., Tumminello G., Di Marco F., Guazzi M.D. Influences of Sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther. 2004; 76: 371–378. DOI: 10.1016/j.clpt.2004.06.003.

27. Lewis G.D., Lachmann J., Camuso J., Lepore J.J., Shin J., Martinovic M.E., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007; 115: 59–66. DOI: 10.1161/CIRCULATIONAHA.106.626226.

28. Muller-Ehmsen J., Whittaker P., Kloner R.A., Dow J.S., Sakoda T., Long T.I., et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol. 2002; 34:107–116. DOI: 10.1006/jmcc.2001.1491.

29. Pagani F.D., Der Simonian H., Zawadzka A., Wetzel K., Edge A.S., Jacoby D.B., et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol. 2003; 41:879–888.

30. Hoke N.N., Salloum F.N., Kass D.A., Das A., Kukreja R.C. Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells. 2012; 30: 326–335. DOI: 10.1002/stem.789.

31. Kukreja R.C. Sildenafil and cardioprotection. Curr Pharm Des. 2013;19(39):6842–6847.

32. Handa P., Tateya S., Rizzo N.O., Cheng A.M., Morgan-Stevenson V., Han C.Y., et al. Reduced vascular nitric oxide-cGMP signaling contributes to adipose tissue inflammation during high-fat feeding. Arterioscler Thromb Vasc Biol. 2011; 31(12):2827–2835. DOI: 10.1161/ATVBAHA.111.236554. Epub 2011 Sep 8.

33. Das A., Durrant D., Salloum F.N., Xi L., Kukreja R.C. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12–21. DOI: 10.1016/j.pharmthera.2014.10.003. Epub 2014 Oct 31.

34. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11: 214–222. DOI: 10.1038/nm1175.

35. Kim K.H., Kim Y.J., Ohn J.H., Yang J., Lee S.E., Lee S.W., et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation. 2012; 125:1390–1401. DOI: 10.1161/CIRCULATIONAHA.111.065300. Epub 2012 Feb 8.

36. Zhang M., Kass D.A. Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci. 2011; 32: 360–365. DOI: 10.1016/j.tips.2011.02.019.

37. Igarashi A., Inoue S., Ishii T., Tsutani K., Watanabe H. Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension. Int Heart J. 2016; 57(4):466–472. DOI: 10.1536/ihj.15-459. Epub 2016 Jul 7.

38. Golden S.H., Robinson K.A., Saldanha I., Anton B., Ladenson P.W. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin.Endocrinol. Metab. 2009; 94:1853–1878. DOI: 10.1210/jc.2008-2291.

39. Flegal K.M., Carroll M.D., Ogden C.L., Johnson CL. Рrevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002; 288: 1723–1727.

40. Geiss L.S., Pan L., Cadwell B. Changes in incidence of diabetes in U.S. adults, 1997–2003. Am. J. Prev. Med. 2006; 30: 371–377. DOI: 10.1016/j.amepre.2005.12.009.

41. Mokdad A.H., Ford E.S., Bowman B.A., Nelson D.E., Engelgau M.M., Vinicor F., et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000; 23: 1278–1283.

42. Schmidt M.I., Duncan B.B. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med. 2003; 41(9):1120–1130. DOI: 10.1515/CCLM.2003.174.

43. Singh H., Venkatesan V. Treatment of «Diabesity»: Beyond Pharmacotherapy. Curr Drug Targets. 2018; 19(14):1672–1682. DOI: 10.2174/1389450119666180621093833.

44. Kouidrat Y., Pizzol D., Cosco T., Thompson T., Carnaghi M., Bertoldo A., et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017; 34(9):1185–1192. DOI: 10.1111/dme.13403. Epub 2017 Jul 18.

45. Corona G., Monami M., Rastrelli G., Aversa A., Sforza A., Lenzi A., et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011; 34(6 Pt 1):528–540. DOI: 10.1111/j.1365-2605.2010.01117.x. Epub 2010 Oct 24.

46. Cai X., Tian Y., Wu T., Cao C.X., Li H., Wang K.J. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and metaanalysis of randomized controlled trials. Asian J Androl. 2014; 16(1):146–152. DOI: 10.4103/1008-682X.122346.

47. Aversa A., Vitale C., Volterrani M., Fabbri A., Spera G., Fini M., et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med. 2008; 25:37–44. DOI: 10.1111/j.1464-5491.2007.02298.x.

48. Kloner R.A., Comstock G., Levine L.A., Tiger S., Stecher V.J. Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. Expert Opin Pharmacother. 2011; 12:2297–2313. DOI: 10.1517/14656566.2011.600306. Epub 2011 Jul 21.

49. Desouza C., Parulkar A., Lumpkin D., Akers D., Fonseca V.A. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002; 25:1336–1339.

50. Stirban A., Laude D., Elghozi J.L., Sander D., Agelink M.W., Hilz M.J., et al. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev. 2009; 25:136–143. DOI: 10.1002/dmrr.921.

51. Grover-Paez F., Villegas R.G., Guillen O.R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 78: 136–140. DOI: 10.1016/j.diabres.2007.02.006.

52. Koka S., Aluri H.S., Xi L., Lesnefsky E.J., Kukreja R.C. Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1alpha signaling. Am J Physiol Heart Circ Physiol. 2014; 306: H1558– H1568.DOI:10.1152/ajpheart.00865.2013. Epub 2014 Apr 11.

53. Behr-Roussel D., Oudot A., Compagnie S., Gorny D., Le Coz O., Bernabe J., et al. Impact of a long-term sildenafil treatment on pressor response in conscious rats with insulin resistance and hypertriglyceridemia. Am J Hypertens. 2008; 21(11):1258–1263. DOI: 10.1038/ajh.2008.273. Epub 2008 Sep 11.

54. Ayala J.E., Bracy D.P., Julien B.M., Rottman J.N., Fueger P.T., Wasserman D.H. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes. 2007; 56(4):1025–1033. DOI: 10.2337/db06-0883.

55. Giannetta E., Feola T., Gianfrilli D., Pofi R., Dall’Armi V., Badagliacca R., et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12: 185. DOI: 10.1186/s12916-014-0185-3.

56. Giannetta E., Isidori A.M., Galea N., Carbone I., Mandosi E., Vizza C.D., et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012; 125: 2323–2333. DOI: 10.1161/CIRCULATIONAHA.111.063412. Epub 2012 Apr 11.

57. Lin Y.C., Leu S., Sun C.K., Yen C.H., Kao Y.H., Chang L.T., et al. Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. J Transl Med. 2010; 8: 88. DOI: 10.1186/1479-5876-8-88.

58. Saraiva K.L., Silva A.K., Wanderley M.I., De Araújo A.A., De Souza J.R., Peixoto C.A. Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion. Int J Exp Pathol. 2009; 90(4): 454–462. DOI: 10.1111/j.1365-2613.2009.00660.x.

59. Mitschke M.M., Hoffmann L.S., Gnad T., Scholz D., Kruithoff K., Mayer P., et al. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J. 2013; 27(4):1621–1630. DOI: 10.1096/fj.12-221580. Epub 2013 Jan 9.

60. Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic Syndrome and Urological Diseases. Rev. Urol. 2010; 12(4): 157–180. DOI: 0.3909/riu0487.

61. Yassin A.A., El-Sakka A.I., Saad F. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Androl. 2008; 40: 259–264. DOI: 10.1111/j.1439-0272.2008.00851.x.

62. Soares M.A., Ezeamuzie O.C., Ham M.J., Duckworth A.M., Rabbani P.S., Saadeh P.B., et al. Targeted protection of donor graft vasculature using a phosphodiesterase inhibitor increases survival and predictability of autologous fat grafts. Plast Reconstr Surg. 2015; 135(2):488– 499. DOI: 10.1097/PRS.0000000000000909.

63. Тюзиков И.А., Калинченко С.Ю., Тишова Ю.А., Ворслов Л.О. Силденафил – новые грани известных фармакотерапевтических опций при лечении эректильной дисфункции. Hi+Med. Высокие технологии в медицине. 2016; 10(47): 58–61.

64. Ramirez C.E., Nian H., Yu C., Gamboa J.L., Luther J.M., Brown N.J., et al. Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2015;100(12):4533– 4540. DOI: 10.1210/jc.2015-3415. Epub 2015 Nov 18.

65. Koppiker N. Use of cGMP PDE5 inhibitors in the treatment of neuropathy: a review of the patent literature. IDrugs. 2002; 5(5):448–453.

66. Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int J Clin Pract. 2006; 60(9):1123–1126. DOI: 10.1111/j.1742-1241.2006.01087.x

67. Jia L., Wang L., Chopp M., Zhang Y., Szalad A., Zhang Z.G. MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions. Neuroscience. 2016; 329: 43–53. DOI: 10.1016/j.neuroscience.2016.05.005. Epub 2016 May 7.

68. Hatzimouratidis K., Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014;14(11): 545. DOI: 10.1007/s11892-014-0545-6.

69. La Vignera S., Condorelli R.A., Vicari E., Lotti F., Favilla V., Morgia G., et al. Seminal vesicles and diabetic neuropathy: ultrasound evaluation after prolonged treatment with a selective phosphodiesterase-5 inhibitor. Androl. 2013; 1(2): 245– 250. DOI: 10.1111/j.2047-2927.2012.00025.x. Epub 2012 Nov 29.

70. Wang L., Chopp M., Szalad A., Liu Z., Bolz M., Alvarez F.M., et al. Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience. 2011; 193: 399–410. DOI: 10.1016/j.neuroscience.2011.07.039. Epub 2011 Jul 27.

71. Patil C.S., Singh V.P., Singh S., Kulkarni S.K. Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. Pharmacol. 2004; 72: 190–195. DOI: 10.1159/000080104.

72. Afsar B., Ortiz A., Covic A., Gaipov A., Esen T., Goldsmith D., et al. Phosphodiesterase type 5 inhibitors and kidney disease. Int Urol Nephrol. 2015; 47(9):1521–1528. DOI: 10.1007/s11255-015-1071-4. Epub 2015 Aug 5.

73. Brown K.E., Dhaun N., Goddard J., Webb D.J. Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension. 2014;63(1):5–11. DOI: 10.1161/HYPERTENSIONAHA.113.01774. Epub 2013 Oct 7.

74. Pofi R., Fiore D., De Gaetano R., Panio G., Gianfrilli D., Pozza C., et al. Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Sci Rep. 2017; 7: 44584. DOI: 10.1038/srep44584.

75. Shen K., Johnson D.W., Gobe G.C. The role of cGMP and its signaling pathways in kidney disease. Am J Physiol Renal Physiol. 2016; 311(4): F671–F681. DOI: 10.1152/ajprenal.00042.2016. Epub 2016 Jul 13.

76. Lasaponara F., Sedigh O., Pasquale G., Bosio A., Rolle L., Ceruti C., et al. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. J Sex Med. 2013;10(11):2798–2814. DOI: 10.1111/jsm.12038. Epub 2013 Jan 24.

77. Vecchio M., Navaneethan S.D., Johnson D.W., Lucisano G., Graziano G., Querques M., et al. Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials. Clin J Am Soc Nephrol. 2010;5(6):985–995. DOI: 10.2215/CJN.09081209. Epub 2010 May 24.

78. Pace G., Palumbo P., Miconi G., Silvestri V., Cifone M.G., Vicentini C. PDE-5 and NOS II mRNA expression in menopausal women: a molecular biology study. World J Urol. 2011;29(2):243–248. DOI: 10.1007/s00345-010-0517-7. Epub 2010 Feb 23.

79. Taskin M.I., Yay A., Adali E., Balcioglu E., Inceboz U. Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats. Gynecol Endocrinol. 2015;31(4):272–277. DOI: 10.3109/09513590.2014.984679. Epub 2014 Dec 8.

80. El-Sayed M.A., Saleh S.A., Maher M.A., Khidre A.M. Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate. J Matern Fetal Neonatal Med. 2018; 31(8): 1045–1050. DOI: 10.1080/14767058.2017.1306509. Epub 2017 Mar 27.

81. Oyston C., Stanley J.L., Oliver M.H., Bloomfield F.H., Baker P.N. Maternal Administration of Sildenafil Citrate Alters Fetal and Placental Growth and Fetal-Placental Vascular Resistance in the Growth-Restricted Ovine Fetus. Hypertension. 2016; 68(3):760–767. DOI: 10.1161/HYPERTENSIONAHA.116.07662. Epub 2016 Jul 18.

82. Russo F.M., Toelen J., Eastwood M.P., Jimenez J., Miyague A.H., Vande Velde G., et al. Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia. Thorax. 2016; 71(6): 517–525. DOI: 10.1136/thoraxjnl-2015-207949. Epub 2016 Mar 17.

83. Tiboni G.M., Ponzano A. Prevention of valproic acid-induced neural tube defects by sildenafil citrate. Reprod Toxicol. 2015; 56: 175–179. DOI: 10.1016/j.reprotox.2015.03.004. Epub 2015 Mar 20.

84. Dunn L., Flenady V., Kumar S. Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial. J Transl Med. 2016; 14: 15. DOI: 10.1186/s12967-016-0769-0.

85. George E.M., Palei A.C., Dent E.A., Granger J.P. Sildenafil attenuates placental ischemiainduced hypertension. Am J Physiol Regul Integr Comp Physiol. 2013; 305(4):R397–403. DOI: 10.1152/ajpregu.00216.2013. Epub 2013 Jun 19.

86. Villanueva-García D., Mota-Rojas D., Hernández-González R., Sánchez-Aparicio P., Alonso-Spilsbury M., Trujillo-Ortega M.E., et al. A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol. 2007; 27(3):255–259. DOI: 10.1080/01443610701194978.

87. Maher M.A., Sayyed T.M., Elkhouly N. Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. Obstet Gynecol. 2017; 129(4): 615–620. DOI: 10.1097/AOG.0000000000001928.

88. Trapani A.Jr., Gonçalves L.F., Trapani T.F., Vieira S., Pires M., Pires M.M. Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial. Obstet Gynecol. 2016; 128(2): 253–259. DOI: 10.1097/AOG.0000000000001518.

89. Paauw N.D., Terstappen F., Ganzevoort W., Joles J.A., Gremmels H., Lely A.T. Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure. Hypertension. 2017; 70(5):998–1006. DOI: 10.1161/HYPERTENSIONAHA.117.09690. Epub 2017 Sep 11.

90. Dunn L., Greer R., Flenady V., Kumar S. Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal Outcomes. Fetal Diagn Ther. 2017; 41(2):81–88. DOI: 10.1159/000453062. Epub 2016 Dec 8.

91. Biyiksiz P.C., Filiz S., Vural B. Is sildenafil citrate affect endometrial receptivity? An immunohistochemical study. Gynecol Endocrinol. 2011; 27(10):767–774. DOI: 10.3109/09513590.2010.540601. Epub 2010 Dec 29.

92. Takasaki A., Tamura H., Miwa I., Taketani T., Shimamura K., Sugino N. Endometrial growth and uterine blood flow: a pilot study for improving endometrialthickness in the patients with a thin endometrium. Fertil Steril. 2010; 93(6):1851–1858. DOI: 10.1016/j.fertnstert.2008.12.062. Epub 2009 Feb 6.

93. Zinger M., Liu J.H., Thomas M. A. Successful use of vaginal sildenafil citrate in two infertility patients with Asherman’s syndrome. J Womens Health (Larchmt). 2006; 15(4):442– 444. DOI: 10.1089/jwh.2006.15.442.

94. Nurnberg H.G., Hensley P.L., Heiman J.R., Croft H.A., Debattista C., Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008; 300(4):395–404.DOI:10.1001/jama.300.4.395.

95. Gao L., Yang L., Qian S., Li T., Han P., Yuan J. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction. Int J Gynaecol Obstet. 2016; 133(2):139–145. DOI: 10.1016/j.ijgo.2015.08.015. Epub 2015 Dec 17.

96. Гамидов С.И., Овчинников Р.И., Попова А.Ю. Мужское бесплодие и эректильная дисфункция: влияние ингибиторов фосфодиэстеразы 5-го типа на сперматогенез. РМЖ. 2015; 11:626.

97. Aversa A., Mazzilli F., Rossi T., Delfino M., Isidori A.M., Fabbri A. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod. 2000; 15(1): 131–134.

98. Purvis K., Muirhead G.J., Harness J.A. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol. 2002; 53(Suppl. 1): 53–60. DOI: 10.1046/j.0306-5251.2001.00033.x

99. Du Plessis S.S., de Jongh P.S., Franken D.R. Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function. Fertil Steril. 2004; 81(4):1026–1033. DOI: 10.1016/j.fertnstert.2003.09.054.

100. Jannini E.A., Lombardo F., Salacone P. Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate. Fertil Steril. 2004; 81(3): 705–707.

101. Drobnis E.Z., Nangia A.K. Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction. Adv Exp Med Biol. 2017; 1034: 29–38. DOI: 10.1007/978-3-319-69535-8_5.

102. Tan P., Liu L., Wei S., Tang Z., Yang L., Wei Q. The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Metaanalysis and Systematic Review. Urol. 2017; 105:54–61. DOI: 10.1016/j.urology.2017.02.032. Epub 2017 Mar 1.

103. Dimitriadis F., Giannakis D., Pardalidis N., Zikopoulos K., Paraskevaidis E., Giotitsas N., et al. Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. Asian J Androl. 2008;10(1):115–133. DOI: 10.1111/j.1745-7262.2008.00373.x

104. Mostafa T. Oral phosphodiesterase-5 inhibitors and sperm functions. Int J Impot Res. 2008;20(6): 530– 536. DOI: 10.1038/ijir.2008.29. Epub 2008 Jul 3.

105. Epstein P.M., Hachisu R. Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984; 16: 303–324.

106. Joe A.K., Liu H., Xiao D., Soh J.W., Pinto J.T., Beer D.G., et al. Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. J Exp Ther Oncol. 2003; 3: 83–94.

107. Lim J.T., Piazza G.A., Pamukcu R., Thompson W.J., Weinstein I.B. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin Cancer Res. 2003;9:4972–4982.

108. Piazza G.A., Thompson W.J., Pamukcu R., Alila H.W., Whitehead C.M., Liu L., et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001; 61: 3961–3968.

109. Singer A.L., Sherwin R.P., Dunn A.S., Appleman M.M. Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues. Cancer Res. 1976; 36: 60–66.

110. Whitehead C.M., Earle K.A., Fetter J., Xu S., Hartman T., Chan D.C., et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther. 2003;2:479–488.

111. Zhu B., Vemavarapu L., Thompson W.J., Strada S.J. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005; 94: 336–350. DOI: 10.1002/jcb.20286.

112. Karami-Tehrani F., Moeinifard M., Aghaei M., Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012; 43:470–475. DOI: 10.1016/j.arcmed.2012.08.006. Epub 2012 Sep 7.

113. Sarfati M., Mateo V., Baudet S., Rubio M., Fernandez C., Davi F., et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood. 2003; 101: 265–269. DOI: 10.1182/blood-2002-01-0075.

114. Li N., Xi Y., Tinsley H.N., Gurpinar E., Gary B.D., Zhu B., et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/betacatenin signaling. Mol Cancer Ther. 2013; 12:1848–1859. DOI: 10.1158/1535-7163.MCT-13-0048. Epub 2013 Jun 26.

115. Tinsley H.N., Gary B.D., Keeton A.B., Lu W., Li Y., Piazza G.A. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila). 2011; 4: 1275–1284. DOI: 10.1158/1940-6207.CAPR-11-0095. Epub 2011 Apr 19.

116. Booth L., Roberts J.L., Cruickshanks N., Tavallai S., Webb T., Samuel P., et al. PDE5 inhibitors enhance Celecoxib killing in multiple tumor types. J Cell Physiol. 2015; 230(5): 1115–1127. DOI: 10.1002/jcp.24843.

117. Das A., Durrant D., Mitchell C., Mayton E., Hoke N.N., Salloum F.N., et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA. 2010; 107: 18202–18207. DOI: 10.1073/pnas.1006965107. Epub 2010 Sep 30.

118. Booth L., Roberts J.L., Cruickshanks N., Conley A., Durrant D.E., Das A., et al. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol. 2014; 85: 408–419. DOI: 10.1124/mol.113.090043. Epub 2013 Dec 18.

119. Roberts J.L., Booth L., Conley A., Cruickshanks N., Malkin M., Kukreja R.C., et al. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther. 2014; 15: 758–767. DOI: 10.4161/cbt.28553. Epub 2014 Mar 20.

120. El-Naa M.M., Othman M., Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther. 2016; 10: 3661-3672. DOI: 10.2147/DDDT.S107490.


Просмотров: 106


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)